The Preventive Role of Angiotensin Converting Enzyme Inhibitors/Angiotensin-II Receptor Blockers and β-Adrenergic Blockers in Anthracycline- and Trastuzumab-Induced Cardiotoxicity

被引:33
|
作者
Blanter, Julia B. [1 ]
Frishman, William H. [2 ]
机构
[1] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA
[2] Westchester Med Ctr, New York Med Coll, Dept Med, Valhalla, NY USA
关键词
cardiotoxicity; chemotherapy; beta-adrenergic blockers; angiotensin converting enzyme inhibitors; angiotensin receptor blockers; VENTRICULAR SYSTOLIC DYSFUNCTION; BREAST-CANCER; HEART-FAILURE; CARDIO-ONCOLOGY; DOXORUBICIN; CARVEDILOL; THERAPY; CANDESARTAN; ENALAPRIL; TRIAL;
D O I
10.1097/CRD.0000000000000252
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Anthracycline (doxorubicin) and trastuzumab treatments for cancer patients have been known to cause cardiotoxicity. The current recommendations for prevention of cardiac events from cancer chemotherapies are largely based on opinion. The American Society of Clinical Oncology recommends active screening and prevention of modifiable cardiovascular risk factors. The risk factors are defined as tobacco use, high blood pressure, high cholesterol, alcohol use, obesity, and physical inactivity. Beta-adrenergic blockers and angiotensin converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARBs) have been the mainstay of treatment for heart failure patients with reduced left ventricular ejection fraction for many years. This review analyzed the use of beta-adrenergic blockers and ACE inhibitors/ARBs as protection against cardiomyopathy caused by anthracyclines and trastuzumab. Although many more studies are warranted, it was concluded that the addition of a beta-blocker early in the treatment of cancer patients who are undergoing anthracycline or trastuzumab treatment can have beneficial effects in preserving left ventricular ejection fraction and preventing chemotherapy-induced cardiotoxicity. The effects are more apparent in the short term. More studies of the long-term effects are warranted, as are the additive effects of using a beta-blocker and ACE inhibitor/ARB together to prevent chemotherapy-induced cardiotoxicity.
引用
收藏
页码:256 / 259
页数:4
相关论文
共 50 条
  • [41] Discontinuation of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Chronic Kidney Disease
    Qiao, Yao
    Shin, Jung-Im
    Sang, Yingying
    Inker, Lesley A.
    Secora, Alex
    Luo, Shengyuan
    Coresh, Josef
    Alexander, G. Caleb
    Jackson, John W.
    Chang, Alex R.
    Grams, Morgan E.
    MAYO CLINIC PROCEEDINGS, 2019, 94 (11) : 2220 - 2229
  • [42] Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Acute Coronary Syndrome: Implications for Platelet Reactivity?
    Tscharre, Maximilian
    Wadowski, Patricia P.
    Weikert, Constantin
    Pultar, Joseph
    Eichelberger, Beate
    Panzer, Simon
    Gremmel, Thomas
    CARDIOVASCULAR DRUGS AND THERAPY, 2021, 35 (06) : 1183 - 1190
  • [43] Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high vascular risk
    Potier, Louis
    Roussel, Ronan
    Elbez, Yedid
    Marre, Michel
    Zeymer, Uwe
    Reid, Christopher M.
    Ohman, Magnus
    Eagle, Kim A.
    Bhatt, Deepak L.
    Steg, Philippe Gabriel
    HEART, 2017, 103 (17) : 1339 - 1346
  • [44] Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension
    Li, Edmond C. K.
    Heran, Balraj S.
    Wright, James M.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2014, (08):
  • [45] Comparing the effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on renal function decline in diabetes
    Huang, Yunyu
    Haaijer-Ruskamp, Flora M.
    Voorham, Jaco
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2016, 5 (03) : 229 - 237
  • [46] Melanoma incidence and exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers
    Koomen, E. R.
    Herings, R. M. C.
    Guchelaar, H. J.
    Nijsten, T.
    CANCER EPIDEMIOLOGY, 2009, 33 (05) : 391 - 395
  • [47] Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers: Anti-arrhythmic Drug for Arrhythmogenic Right Ventricular Cardiomyopathy
    Tu, Bin
    Wu, Lingmin
    Zheng, Lihui
    Liu, Shangyu
    Sheng, Lishui
    Liu, Limin
    Zhu, Zhenghui
    Yao, Yan
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2021, 8
  • [48] Role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in cryoballoon ablation outcomes for paroxysmal atrial fibrillation
    Al-Seykal, Ibragim
    Bose, Abhishek
    Chevli, Parag A.
    Hashmath, Zeba
    Sharma, Nitish
    Mishra, Ajay K.
    Laidlaw, Douglas
    WORLD JOURNAL OF CARDIOLOGY, 2022, 14 (10): : 537 - 545
  • [49] Role of Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Aldosterone Antagonists in the Prevention of Atrial and Ventricular Arrhythmias
    Makkar, Kathy M.
    Sanoski, Cynthia A.
    Spinler, Sarah A.
    PHARMACOTHERAPY, 2009, 29 (01): : 31 - 48
  • [50] Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in cancer progression and survival: a systematic review
    Mc Menamin, Una C.
    Murray, Liam J.
    Cantwell, Marie M.
    Hughes, Carmel M.
    CANCER CAUSES & CONTROL, 2012, 23 (02) : 221 - 230